Chemical Data :

IUPAC: 7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one

CAS: 2647-50-9

ChemSpider: 10441497

Molecular Weight: 333.16

Molecular Formula: C15H10BrFN2O

Flubromazepam is an anxiolytic drug compound of the benzodiazepine class. It is classified as one of the longer lasting benzos.

Flubromazepam was first synthesised in 1960, but failed to reach the market. It resurfaced in late 2012 as a “research chemical” sold by online vendors for use as a recreational psychoactive.

Flubromazepam has the formal and systematic IUPAC name 7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one.

It derives its common name from the bromine and fluorine substitutions which are made on the basic benzodiazepine skeleton.  This structural backbone consists of a 1, 4 diazepine ring which is fused to a benzene ring. The fused benzene ring is substituted with a bromine atom. Within the bicyclic structure this substitution is at R7. A fluorine substituted phenyl ring is substituted on to the bicyclic structure at R5. It also has an oxygen substitution at R2 to form a ketone group. All “-azepam” benzodiazepine compounds have the R2 ketone.

Flubromazepam produces its variety of effects by binding at an allosteric site on the GABAa protein. While bound at this position Flubromazepam will increase the efficiency of the endogenous GABA allowing the GABAa receptor to stay open longer when GABA binds. GABA is the main inhibitory neurochemical in the mammalian nervous system. This modulation of the GABAa receptor produces sedation and anxiolytic effects.

Flubromazepam is not a licensed medicine. It is not for human or animal consumption.

Unverifiable online reports can give some insight in to the subject effects of Flubromazepam.

Flubromazepam is reported as being heavily sedating. Users are reported as finding themselves in an overwhelmingly lethargic state and at higher doses will generally force the individual in to a sleep state. Other physical effects which are reported are a suppression of thought, loss of short term memory, loss of inhibition, feelings of dizziness, relaxation of the muscle and physical euphoria. It is reported that individuals often feel more sober than they actually are.

A range of cognitive effects have been published online in user experiences that correlate with a typical benzodiazepine action. Users have reported a marked lowering of anxiety and reduction in the strength of their emotions. Flubromazepam may cause users to compulsively re-dose.

It is important to be aware that Flubromazepam, as with other benzodiazepines, is highly physically and psychologically addictive. After a few days of continuous use of this compound a tolerance will develop to the sedative effects. Highly distressing withdrawal effects may manifest during a cessation period if the individual had previously been using Flubromazepam over a long period. This can include rebound insomnia and anxiety.

With all benzodiazepines, short term use is much preferred. If, after a long period of use, one wants to stop, it should be done in a manner to gradually taper off the dose, not stop abruptly. Stopping abruptly will produce the worst withdrawal effects.

It is highly dangerous to combine Flubromazepam with other depressive drugs. This includes dissociatives such as Ketamine and DXM, alcohol, GHB/GBL, opioids and others. Such combinations increase the likelyhood of respiratory failure and death. Combination with stimulants is also dangerous and can be lethal.

Other names and synonyms :

2647-50-9 [RN]
2H-1,4-Benzodiazepin-2-one, 7-bromo-5-(2-fluorophenyl)-1,3-dihydro- [ACD/Index Name]
7-Brom-5-(2-fluorphenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on [German] [ACD/IUPAC Name]
7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one [ACD/IUPAC Name]
7-Bromo-5-(2-fluorophényl)-1,3-dihydro-2H-1,4-benzodiazépin-2-one [French] [ACD/IUPAC Name]
Flubromazepam [Wiki]
MFCD22055975 [MDL number]

Chemical Data

IUPAC: 7-bromo-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

Smiles: FC1=C(C=CC=C1)C1=NCC(=O)NC2=CC=C(Br)C=C12

InChI: 1S/C15H10BrFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)


Formula: C15H10BrFN2O
Isotope formula: C15H10BrFN2O
Composition: C (54.08%), H (3.03%), Br (23.98%), F (5.7%), N (8.41%), O (4.8%)
Isotope composition: C (54.08%), H (3.03%), Br (23.98%), F (5.7%), N (8.41%), O (4.8%)
Mass: 333.155
Exact mass: 331.996053804

Atom count: 30
Bond count: 32
Cyclomatic number: 3
Chain atom count: 3
Chain bond count: 4
Asymmetric atom count: 0
Rotatable bond count: 1
FSP3: 0.07

Ring Count: 3
Ring atom count: 17
Ring bond count: 18
Aliphatic ring count: 1
Aromatic ring count: 2
Aliphatic atom count: 8
Aliphatic bond count: 10
Aromatic atom count: 12
Aromatic bond count: 12
Carbo ring count: 2
Hetero ring count: 1
Heteroaromatic ring count: 0
Carboaromatic ring count: 2
Fused ring count: 2
Fused aliphatic ring count: 0
Fused aromatic ring count: 0
Largest ring size: 7
Smallest ring size: 6

Platt index: 62
Randic index: 9.65
Balaban index: 1.62
Harary index: 69.29
Wiener index: 729
Hyper Wiener index: 2089
Wiener polarity: 35
Szeged index: 1236